

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

26 February 2025

The Manager Companies  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

(2 pages by email)

Dear Shareholders,

**BIOTRON INVESTOR WEBINAR**

**Investor Webinar | 11am AEDT – Tuesday 04 March 2025**

You are invited to register using this link:


[https://us06web.zoom.us/webinar/register/WN\\_-AXldDnLSdCOMHfVAaFwfQ](https://us06web.zoom.us/webinar/register/WN_-AXldDnLSdCOMHfVAaFwfQ)

*Participants may submit questions during registration or during the session*

**Biotron Limited (ASX: BIT)** Chairman Michael Hoy & Managing Director Michelle Miller will conduct an **Investor Webinar** on 11am AEDT on Tuesday 04 March 2025 to outline Biotron's latest developments and commercial trajectory:

- **BIT225 HIV-1 Phase 2 Clinical Trials Met Primary Objectives:**
  - BIT225 was safe and generally well tolerated with no deaths or drug-related adverse events.
  - BIT225 treated cleared virus faster than those on ART alone.
  - BIT225 induced statistically significant changes in specific immune cell populations, markers and cytokines.
- **Progress in Early-Stage Programs** – Advances in **Hepatitis B and Dengue Virus** programs reinforce Biotron's potential across multiple infectious diseases.
- **Commercialisation Strategy** – Ongoing collaboration with **US-based C14 Consulting Group** to secure strategic partnerships, commercialise clinical and pre-clinical assets, including platform technologies.
- **Share Purchase Plan (SPP)** – Offering eligible shareholders an opportunity to participate in Biotron's growth at \$0.01 per share.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn12527

### **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and SARS-CoV-2 as well as a promising preclinical program for Hepatitis B Virus. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. This announcement has been approved by the Company's Managing Director.

### **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333